Pharma BD Deal Intelligence
Teva's $40.5B bet on Actavis Generics is one of pharma's worst-aged mega-deals: debt ballooned from roughly $10B to ~$35B, triggering a $17.1B impairment in 2017, a suspended dividend, and a 25% workforce cut—a crisis Teva is only now emerging from a decade later.
Teva's $40.5B bet on Actavis Generics is one of pharma's worst-aged mega-deals: a $17.1B single-year impairment, debt that nearly broke the company, a 25% workforce cut, and a decade-long crisis it is only now emerging from.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Wharton analysis framed the deal as Teva's pivot to scale-driven generics dominance and a hedge against Copaxone biosimilar erosion, while flagging integration…
Investors filed suit alleging Teva concealed deteriorating U.S. generic pricing dynamics during the Actavis deal process, reinforcing the consensus that the…
Ten-year retrospective concluded the Teva-Actavis deal was 'by most measures a failure,' citing massive goodwill impairments, debt overhang, and management…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Teva completed acquisition of Allergan's global generics business (Actavis Generics) for $40.5B: $33.43B in cash plus ~100M Teva shares. FTC required Teva divest 79 generic drug assets to Dr. Reddy's, Aurobindo, Cipla, Mayne, 3M, and others. Made Teva the world's largest generic pharma. Originally announced July 26, 2015; closed August 2, 2016.
Teva's $40.5B bet on Actavis Generics is one of pharma's worst-aged mega-deals: a $17.1B single-year impairment, debt that nearly broke the company, a 25% workforce cut, and a decade-long crisis it is only now emerging from.
Assessment window: 5yr post-close.
The Actavis Generics business spans the full therapeutic generic spectrum — cardiovascular, CNS, oncology, women's health, complex injectables and topicals. Generics fill roughly 90% of U.S. prescriptions but face structural margin compression from consolidated buyer purchasing groups and FDA-driven generic approval acceleration.
Teva's $40.5B acquisition of Allergan's Actavis Generics (closed August 2, 2016) combined the world's #1 and #3 generics platforms, leapfrogging Sandoz (Novartis) and Mylan to make Teva the unambiguous global generics leader. Consideration was $33.43B cash plus ~100M Teva shares; the FTC required divestiture of 79 generic drug assets to Dr. Reddy's, Aurobindo, Cipla, Mayne, and 3M to clear antitrust. The strategic logic — scale to offset Copaxone biosimilar erosion and improve generic pricing power against U.S. consolidated buyer groups (Red Oak, Walgreens Boots Alliance, ClarusONE) — proved largely flawed. Citeline's ten-year retrospective called the deal 'by most measures a failure', citing $35B+ goodwill impairments, leverage that triggered a credit downgrade, and an executive exodus including the head of generics within months of close. Competitors Sandoz, Sun Pharma, Mylan and Indian players Dr. Reddy's and Aurobindo gained share during Teva's integration distraction.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Allergan plc (Actavis Generics business) (this deal) | 2016 | $40.5B | 24 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2016 deals · Teva Pharmaceutical Industries Ltd. deals · Other deals